Fraud, Lies, Exploitation and Eugenic Fantasies
By Emile P. Torres,
Truthdig
| 11. 09. 2023
It’s been a no good, very bad year for Effective Altruism, or “EA” for short, the cultural movement that aims to use “evidence and reason” to figure out the best ways to do the “most good.”
One year ago, the EA community was flying high. Its poster boy, a philosopher named William MacAskill, had just published his book “What We Owe the Future,” which makes the case that we should be far more concerned about humanity’s long-term future — thousands, millions, even billions of years from now — than we ordinarily are. Effective Altruists call this “longtermism,” an idea built around a vision of the future in which we reengineer humanity, colonize space, plunder the vast resources of the cosmos, and ultimately maximize the total amount of “value” in the universe by creating huge numbers of “digital people” living “happy” lives in giant computer simulations.
If this sounds bizarre and potentially dangerous, that’s because it is. Yet MacAskill’s book, longtermism and the EA movement that he co-founded received mostly favorable coverage from...
Related Articles
By Liyan Qi and Jonathan Cheng, The Wall Street Journal | 03.26.2025
photo via Wikimedia Commons licensed under CC by 3.0
Chinese scientist He Jiankui set off global outrage and landed in prison after he skirted ethical guidelines and claimed he had produced genetically modified babies designed to resist HIV infection.
Now, the self-styled ...
By Carsten T. Charlesworth, Henry T. Greely, and Hiromitsu Nakauchi, MIT Technology Review | 03.25.2025
Why do we hear about medical breakthroughs in mice, but rarely see them translate into cures for human disease? Why do so few drugs that enter clinical trials receive regulatory approval? And why is the waiting list for organ transplantation...
By Anna Louie Sussman, The New York Times | 03.25.2025
On June 24, 2022, the same day the Supreme Court issued its decision in Dobbs v. Jackson Women’s Health Organization, I received a call from the fertility clinic where I’d been undergoing in vitro fertilization, informing me that seven of...
By Michael Gibney, PharmaVoice | 03.20.2025
The death this week of a teenager receiving Sarepta Therapeutics’ gene therapy Elevidys for Duchenne muscular dystrophy is a tragic reminder of the stakes involved in cutting-edge biotech innovation.
While gene therapies like Sarepta’s offer an opportunity to treat and...